Clopidogrel Tablet, Film Coated
Product Images NDC 71205-073

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 71205-073). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Clopidogrel Fig1)

This is a figure (Figure 1) that shows the exposure to the active metabolite of Clopidogrel (a medication used to prevent blood clots) following multiple doses of 75 mg alone or with proton pump inhibitors (PPIs). The figure includes a graph with bars representing the effect of co-administered PPI on active metabolite AUC (an indicator of drug exposure) along with mean values and 90% confidence intervals. The PPIs included in the figure are Dexlansoprazole (60 mg), Lansoprazole (30 mg), Pantoprazole (80 mg), and Omeprazole (80 mg). The graph also shows relative changes in comparison to the administration of Clopidogrel Bisulfate alone.*

FDA Label Image

Figure 2: Cardiovascular Death, Myocardial Infarction, And Stroke In The Cure Study (Clopidogrel Fig2)

This text appears to be a table showing the "Cumulative Event Rate (%)" for various medical conditions, including "Cardiovascular death, myocardial infarction, and stroke," measured over a 12-month period. The table compares the effects of a Plagebo treatment plus aspirin versus Clopidogrel Bisulfate plus aspirin, with other standard therapies used as appropriate. The P-value is also provided as 0.00009.*

FDA Label Image

Figure-3 (Clopidogrel Fig3)

This appears to be a table of data regarding a study examining the use of various medications and treatments for patients with particular conditions, such as diabetes and previous strokes. The table includes information on various subgroups divided by age and gender, as well as the efficacy of certain medications compared to a placebo group. Additionally, there is a hazard ratio shown at the bottom of the table.*

FDA Label Image

Figure 4: Cumulative Event Rates For Death In The Commit Study (Clopidogrel Fig4)

This appears to be a statistical report related to a medical study that involved a placebo and clopidogrel. The report includes the number of deaths before the first discharge and a comparison between the two treatments regarding proportional risk reduction. The text also shows a graph displaying the days since randomization.*

FDA Label Image

Figure 5: Cumulative Event Rates For The Combined Endpoint Re-infarction, Stroke Or Death In The Commit Study (Clopidogrel Fig5)

This appears to be a statistical report related to a clinical trial comparing the effectiveness of Placeb and Clopidogrel in preventing certain events. The report mentions the number of participants with events and the percent for each group, as well as a proportional risk reduction and p-value. It also includes a graph showing how events varied over time after randomization.*

FDA Label Image

Figure 6: Effects Of Adding Clopidogrel Bisulfate To Aspirin On The Combined Primary Endpoint Across Baseline And Concomitant Medication Subgroups For The Commit Study (Clopidogrel Fig6)

This is a table presenting data from a clinical trial where patients were given either a drug called Clopidogrel Bisulfate or a placebo and evaluated for various factors, such as subgroup, gender, age, hours since onset, heart rate, and Fibrinolytic agent given. The table also shows the percentage of patients in each group favoring Clopidogrel Bisulfate or placebo, with odds ratios and confidence intervals. No meaningful conclusion can be drawn from this table without additional information about the study design and other variables.*

FDA Label Image

Figure 7: Fatal Or Non-fatal Vascular Events In The Caprie Study (Clopidogrel Fig7)

The text is a graph showing the cumulative event rate (percentage) for fatal or non-fatal vascular events when using Aspirin and Clopidogrel Bisultate. It also shows the months of follow-up.*

FDA Label Image

Figure 8: Hazard Ratio And 95% Ci By Baseline Subgroups In The Caprie Study (Clopidogrel Fig8)

This appears to be a table with information related to different qualifying conditions and the use of medications like Clopidogrel Bisulfate and Aspirin in treating these conditions. The conditions mentioned are Stroke, Mi, and PAD, with the total number of cases being 19185. The table also shows the number of cases in which each medication was used and the corresponding percentage. The last row of the table mentions the favors and their corresponding years. The text also indicates the presence of a hazard ratio along with its confidence interval of 95%.*

FDA Label Image

71205-073-90 (Clopidogrel Fig9)

This is a description of a medicine labeled Clopidogrel 75mg with 30 tablets. The tablets are round, pink in color, and are specially coated. The medication should be kept in a cool dry place and out of children's reach. The medicine comes with an instruction guide which should be given to each patient. The medicine was manufactured by Aurobindo Pharma Limited, Hyderabad, India. The medication has lot #00000, and its product ID is SC007330. It is also labeled with GTIN: 0371205073305.*

FDA Label Image

Chemical Structure (Clopidogrel Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.